These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 7927707)

  • 21. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.
    Welch PG; Fattom A; Moore J; Schneerson R; Shiloach J; Bryla DA; Li X; Robbins JB
    J Am Soc Nephrol; 1996 Feb; 7(2):247-53. PubMed ID: 8785394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines.
    Fattom A; Cho YH; Chu C; Fuller S; Fries L; Naso R
    Vaccine; 1999 Jan; 17(2):126-33. PubMed ID: 9987146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate.
    Griffin TJ; Thanawastien A; Cartee RT; Mekalanos JJ; Killeen KP
    Hum Vaccin Immunother; 2019; 15(6):1310-1316. PubMed ID: 31021700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
    Meena J; Kumar R; Singh M; Ahmed A; Panda AK
    Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.
    Tacket CO; Ferreccio C; Robbins JB; Tsai CM; Schulz D; Cadoz M; Goudeau A; Levine MM
    J Infect Dis; 1986 Aug; 154(2):342-5. PubMed ID: 2425009
    [No Abstract]   [Full Text] [Related]  

  • 26. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
    Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
    Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
    J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.
    Canh DG; Lin FY; Thiem VD; Trach DD; Trong ND; Mao ND; Hunt S; Schneerson R; Robbins JB; Chu C; Shiloach J; Bryla DA; Bonnet MC; Schulz D; Szu SC
    Infect Immun; 2004 Nov; 72(11):6586-8. PubMed ID: 15501790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.
    Acharya IL; Lowe CU; Thapa R; Gurubacharya VL; Shrestha MB; Cadoz M; Schulz D; Armand J; Bryla DA; Trollfors B
    N Engl J Med; 1987 Oct; 317(18):1101-4. PubMed ID: 3657877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isotypes of human vaccinal antibodies to the Vi capsular polysaccharide of Salmonella typhi.
    Brugier JC; Barra A; Schulz D; Preud'homme JL
    Int J Clin Lab Res; 1993; 23(1):38-41. PubMed ID: 8477090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.
    Devi SJ; Zollinger WD; Snoy PJ; Tai JY; Costantini P; Norelli F; Rappuoli R; Frasch CE
    Infect Immun; 1997 Mar; 65(3):1045-52. PubMed ID: 9038314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
    Robbins JD; Robbins JB
    J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization.
    Keddy KH; Klugman KP; Hansford CF; Blondeau C; Bouveret le Cam NN
    Vaccine; 1999 Jan; 17(2):110-3. PubMed ID: 9987143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice.
    Fiorino F; Ciabattini A; Rondini S; Pozzi G; Martin LB; Medaglini D
    Vaccine; 2012 Sep; 30(43):6111-4. PubMed ID: 22705173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.
    Rondini S; Micoli F; Lanzilao L; Hale C; Saul AJ; Martin LB
    Clin Vaccine Immunol; 2011 Mar; 18(3):460-8. PubMed ID: 21248155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization.
    Klugman KP; Koornhof HJ; Robbins JB; Le Cam NN
    Vaccine; 1996 Apr; 14(5):435-8. PubMed ID: 8735556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgA and IgG1 Specific to Vi Polysaccharide of
    Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
    Front Immunol; 2019; 10():2582. PubMed ID: 31781100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.